London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Muck165, 17 Jun 2024 19:33
Last post: Muck165, 17 Jun 2024 19:33
But might be of interest to some on here…
https://www.theguardian.com/world/article/2024/jun/17/boss-us-firm-uk-covid-contracts-accused-squandering-millions-on-jets-properties
Innova had a positive and negative effect for companies like ABDX I think.
On the plus side the U.K. decision to pursue mass testing introduced LFT’s to the masses, and opened eyes to their benefits which subsequently encouraged diverse development.
On the flip Innova tests were just rubbish, leaving many with mistrust that still pervades, but which the industry is striving to overcome with an explosion of tech advancements.
Started: teraferma, 17 Jun 2024 11:57
Last post: teraferma, 17 Jun 2024 11:57
With billions of lateral flow assays going to landfill, we are proud to be bringing biodegradable housings to the market with Morrama | Certified B Corp.
Check out 360Dx's article on exactly this below.
Test Developers Using Cellulose, Gelatin, Chewing Gum to Make Sustainable Lateral Flow Assays
https://www.360dx.com/business-news/test-developers-using-cellulose-gelatin-chewing-gum-make-sustainable-lateral-flow
Need some solid news to get this share moving northwards.
Last post: Muck165, 16 Jun 2024 11:14
Of course there’s one other significant advantage, which is that as far as I can tell we are likely to be first to market (anywhere) with a universal sustainable LFT cassette.
That's why our government initially sought out and trusted this company to meet the needs of the country during a crisis and, without wishing to reopen old story lines, are one of the few companies who have gained some justice for events that didn't work in their favour at that time. Its all coming good here. Very good IMO.
It is exciting isn’t it.
It’s something end users value, whether that be retail customers or national healthcare organisations/governments. If end users want it, developers will want it. And it’s product and developer agnostic, so we can offer it to them all, everywhere.
But in particular, anyone using our CDMO services will be offered it as part of that service, which is great for attracting new CDMO customers.
Yes, thank you so much Muck, this is really, really exciting research. There can't be anyone who bothers to read all your findings, who can be in any doubt that this is a serious company who can reward our patience generously.
Yet more superb research Muck, cheers.
My best takeaway is just towards the end of the piece. " . . . . Abingdon Health's ambition is for the new design to become the "gold standard of lateral flow housings," Currivan added, and to eventually replace the plastic designs on the market.
Currivan noted that since Abingdon Health not only makes its own kits but manufactures them for others, these innovations could have market-wide ramifications as others adopt them. . . . ".
And that market is immense.
Started: Muck165, 15 Jun 2024 01:46
Last post: Apre, 15 Jun 2024 11:09
Hi Muck, of course, that old chestnut . . . 'economies of scale'.
It's looking promising.
Morning Apre.
You’d hope! Remember also that Yates has said our margins improve as we put more manufacturing volume through the business. See here at about 1.48 in
https://www.youtube.com/watch?v=aHh2Kuw-vzA
So it would seem that increasing Salistick sales won’t just improve top line revenue, but margins as well.
Top sleuthing Muck. Thank you.
All that perhaps backs up Bell's (confident?) assertion about a 'material' increase in revenue . . . he has a full view of the scope of the operation. And my layman's view is that long before the products hit the shelves as far afield as Norway, Israel, Malta etc, the had to be ordered form the manufacturer . . . and paid for.
Another one, this time through Farmasiet which is Norway’s largest online pharmacy. Different packaging, different but exactly the same product. Which we make.
https://www.farmasiet.no/catalog/intim-og-underliv/graviditet-og-egglosning/addeira-salistick-spytt-graviditetstest,5106089?experiments=ai_search&searchQuery=
Just another little one from me.
I think some get confused and think Salistick is just in Superdrug, Tesco, Boots (U.K. under own brand), and Amazon. It’s not.
It’s launched in Israel and is on the shelves and online through its largest pharmacy retailer, Superpharm, which has over 290 stores.
It’s offered by Addeira in Sweden through Apoteket AB, a state owned retailer 400 stores and online, with Apoteket Hjärtat, a Swedish private retailer with a rapidly growing online business and nearly 400 pharmacies, and with Kronans Apotek, Swedens third largest retailer with 300 stores and online. And now we know they are at least offering it in Norway through Boots, and their latest LinkedIn post shows they will shortly be opening up the Danish market.
And to be honest, all this only tells part of the current distribution story. There are plenty of other retailers selling it.
The point, of course, is again to say that Addeira do not make the tests - they are just the supplier. We make, and get paid to make, part of every single test sold no matter where it’s sold, and it’s being sold far more widely than I think a lot of people think.
https://www.apoteket.se/produkt/addeira-gravtest-1-st-ask-1565701/
https://www.kronansapotek.se/addeira-saliv-graviditetstest/p/797762/
https://www.apotekhjartat.se/produkt/addeira-salistick-graviditetstest-saliv-1st/
Started: Viking.Raider, 15 Jun 2024 10:26
Last post: Muck165, 15 Jun 2024 10:48
It’s a “medical device” under the regulations, and requires FDA approval before it can be sold in the US. We know they started engaging with the FDA by at least November 2021 by filing a FDA Q submission, which is explained here
https://www.abingdonhealth.com/lateral-flow-development-fda-qsubmission-processed-explained/
I suspect that as part of that process the FDA May have told Salignostics to do further trials before submitting a full application, particularly as this will be the first ever saliva pregnancy test and so there’s no pre existing market equivalent.
But whatever, you’d hope that here, nearly 3 years later, approval can’t be that far away.
Does it need FDA approval for sale in USA it's not a drug ????.
Last post: Muck165, 14 Jun 2024 15:10
@Apre - as you intimate, it all comes down to what Yates sees as “material”. I’m certainly expecting north of £2.9m for the period, but am hoping for nearer £4.5m alongside cost control. There is just nothing coming out of the company that gives me any cause for concern. If there is a frustration, and I’m certain it must equally frustrate ABDX and developers, is the slow regulatory approval pace. That’s why Ivdeology was a shrewd purchase, and in that respect it’s always worth remembering the sellers sold it for 100% paper at prevailing prices, so they must have confidence in us too.
Wind
Apre is just a sad belligerent person and not invested in either company
Well, ok but I am not underwater here nor the other stock we share, ridicule away if it makes you happier.
Yes Wynbore . . . I know . . . we know . . . we all know . . . you have told us the same thing over and over again, ad nauseam, on multiple boards, for the last four years or so . . .
Just one of the reasons why I have you on my 'ridicule only' list.
Apre, the chart already indicates this has a better chance of going up than going down.
I agree small caps are not the best advocates for TA, but I have found Charts very useful to time entry and exit once I have identified a stock that seems to have growth potential. each to his own
Started: Muck165, 12 Jun 2024 14:08
Last post: Muck165, 12 Jun 2024 14:08
Yates and Stuart Angell are at the Medtech summit at the moment. A couple of Linkedin posts here for info;
https://www.linkedin.com/posts/activity-7206588716625113089-HfCz?utm_source=share&utm_medium=member_desktop - highlights improvements in FDA approval process and confirms we are helping customers through the process
And here's one on about sustainable solutions (see also Yates comment on it)
https://www.linkedin.com/posts/stuartangellivd_as-always-a-wonderful-and-thought-provoking-activity-7206598740487356416-Ypqw?utm_source=share&utm_medium=member_desktop
I’d just add, Yates has said he thinks we need £8-9m for full year operational breakeven, so my the £5m half yearly number might be toppy! If that’s the case then it only improves matters.
The bubbling concern here is always our cash position and the possibility of a raise.
Yates has repeatedly expressed distaste for discounted raises and said we won’t need one in 2024. But let’s look at the numbers.
We had £2m at 31/12. Assuming 53% margin remains stable and half yearly overheads controlled at c£2.7m, then by my reckoning we’d need H2 revenue of c£5m to return a breakeven operational position and maintain cash. Anything less would see cash go down, and anything more see it rise.
We did £2.9m in H2 2023, so £5m is about a 72% increase. I’d be over the moon with that but see it as a stretch target even though we saw 117% in like for like H1 growth. Yates has nonetheless said he’s targeting a material increase and indicated this will be achieved. By my reckoning, and making the same margin/cost assumptions;
- A modest 25% increase in revenue would see cash deplete to £1.25m
- A reasonable 50% increase would see cash deplete to £1.6m
- 72% would see us maintain £2m cash
- Anything more would see cash rise.
The point being that in any of these scenarios I can’t see the need for a raise, particularly given that direction of travel is an ever improving revenue position with tight cost control.
Nice to have you back HD2U!
Alongside what appears to be positive technicals, we might get news anytime on Eco-Flo, the last FOFH design freeze, other FOFH news, Upfront UKCA, Septiloop sales, Salistick FDA approval, or maybe something entirely surprising.
But those are all still “mights”. What we will get is a TU which should come very early in July, and it’s that TU and associated outlook comments which I’m very much looking forward to! ABDX have quietly, prudently and shrewdly repositioned, built a diverse proposition and exciting customer base, and are now firmly entering the next and more significant commercial stage.
The market’s primed. News is coming. I’m very happy to be in and holding and if I could I’d lump more in I would. It’s just very difficult for me to see a downside here.
Let’s hope everything works out and the 30% profit you hold onto still represents a great win.
Evening All,
This is my first post for ages! I won't go there but I been very busy, begins with D and ends with orce so my cow of a soon to be ex wife would like her probably 70% of any profit made with ABDX....All good! I'm bitter at all 😀
Anyway, I have not been posting but have remained in and checking in on here. I agree, this now looks very primed and ready for a leg up!
I'm telling you Muck... you're a natural TA'er! :0))
Started: Muck165, 10 Jun 2024 22:50
Last post: Muck165, 10 Jun 2024 22:50
I’m becoming more convinced that the FOFH STI tests are based on Senzo’s ALF platform.
Our collaboration with Senzo was announced March 2023.
Senzo secured £1.4m October 2023 and they confirmed they were working on STI, HIV, and Hep B/C tests at that time.
In December Senzo’s VP of QA and Reg affairs confirmed he’d put in place all protocols to enable post design freeze trials/analysis. At the same time Senzo put out a detailed blog on STI testing.
In March this year we announced design freeze on 4 STI tests with a fifth coming, and a £500k investment to acquire 23% of FOFH. We announced at the same time that we’d been working with FOFH/Devyn for 12 months, mirroring exactly the collaboration period with Senzo, and only then did a lady working for Senzo VC backers start reacting to all ABDX posts related to FOFH.
Everything ties together in my mind, and in truth it’s the best reason I can think of to explain why Yates would commit 12.5% of previous year revenue, in times where achieving breakeven has been paramount, to acquire just 23% of a company ostensibly operated by a one man band entrepreneur with no history or web presence.
The STI market is massive and growing, particularly in the US. It’s also a market that lends itself perfectly to discrete rapid tests that can be done at home, and a suite of tests offering PCR level performance has every potential to dominate. And we should remember that in 2021 Senzo was selected to join (and remains in) the worlds largest MedTech Innovator accelerator programme, which has an extremely high commercial success rate, and that its staff numbers are growing (alongside fantastic staff reviews of the company) despite appearing commercially inactive - something is happening there.
I think FOFH could be massive. If it is based on Senzo tech then commercial potential is huge - we’d own 23% of all developer rights/IP, would be making and distributing the tests, and would have rights to offer them under own brand labels. The kind of opportunity that Yates just couldn’t ignore.
Could be wrong, but I’m betting I’m not. Ignore as you wish - happy to post supporting links should anyone want them.
GLA
Last post: wyndrum, 10 Jun 2024 09:49
No idea muck, but using HL platform the SP has been moving by 5% up and down for a few trading days now.
The chart showed the break above 11p (11.2p high) and then fell back to 11p.
So at the moment this is confirming the break of 11p, as the resistance has transformed into a support level.
It keeps trying to go up and it does look as though there is a seller out there that is holding the SP down, but that seems to be having the effect of allowing new buyers to come into what is seen as a good value price.
So the chart is performing as expected (so far) but it is on a bit of a knife edge. But as I am fond of saying, you need a plan, and if the plan is falling into place then at some stage, you need to pull the trigger....
gla
Probably a stupid question, but is there any link between Singer trying to shift stock and their removal as our sole broker/Nomad last month?
Doubt it, but thought I'd ask!
The closing price was based on the after hours UT trade. The price will be marked down accordingly in the morning back to the 10.5 - 11.5 spread.
I often see closingUT prices on potential breakout plays, can be a MM trick to trigger liquidity in either direction.
What you can't see unless you have RSP is the supply side as SING seem to have plenty of stock to offload so 11.50 is going to be a tough level to crack.
GLA
Hmm... its closed at 11.20p.... so its broken the level but not by much....
There are always 2 options : it either goes up or down.
If it goes down from here, then it will be close enough to the 11p celling to be part of the resistance but with a small, new level of 11.2p to be breached.
Or
It moves away further up tomorrow and in hindsight it will be clear that the resistance once broken, paved the way for a new, higher trading range.
This is now a difficult call, so some risk averse buyers will probably wait for a clearer direction before committing further or new funds. This is also where the MM's might get involved and move the SP both up and down to see if this sparks a reaction.
So move it up and if floods of buyers come in (great), or move it down and see if floods of sellers arrive.
Volume will be interesting no matter what the outcome.
Its a game, thats for sure....
There seems to be a significant overhang at 11p, are shares being forward sold?
With a change of broker recently, and a bit of M&A as well, do they need some capital?
Hope I'm wrong.
Started: Muck165, 20 May 2024 01:31
Last post: Muck165, 5 Jun 2024 22:25
Just another small point for info, but the paper detailing the Upfront trial results (which I posted at the beginning of this thread) was peer reviewed by this guy.
https://phoenixmed.arizona.edu/newsroom/news/andrei-alexandrov-md-joins-college-chair-department-neurology
Not too shabby and further shows the highly professional way Upfront are being as they continue their path towards commercialisation.
For info, quite a detailed article about the LVOnetest from yesterday.
https://www.clinicalresearchnewsonline.com/news/2024/06/04/blood-test-could-improve-diagnosis-of-severe-strokes-on-a-global-scale
This is why Abingdon is so confident that they will be in profit this year, becoming self sustaining as a company. Alongside Salistic in Boots and Tesco's and sales of their iron defiency tests looks like they'll be up and running in 2024. Be nice if the 5 std tests got accredited this year too. All to play for. Thx for sharing Muck165.
Two little thing I did notice in the video;
- Each LVOne test actually comprises 2 LFT’s.
- They confirmed that their manufacturing partner, “based in York” has already made 20,000 “tests”, so 40,000 individual LFT’s.
So if this gets off the ground, and every indication is it will, then the manufacturing requirement will actually be double the “tests” sold.
Upfront posted this video to explain their history, product, and long collaboration with North East hospitals. 20 mins and worth a watch
https://www.youtube.com/watch?v=Tv1ls6QasiY
Started: Muck165, 29 May 2024 12:46
Last post: wyndrum, 3 Jun 2024 17:52
Added a few more today. The chart is back to the (reasonably tough) resistance level of 11p.
If it breaks it there should be a little bit of a dam breaking. (the stronger the resistance, the bigger the move tends to be once breached, the logic being that sellers at (in this example), 11p are exhausted, so if no one is selling and there are people who want to buy.... then that only leaves one direction to go in.)
The odds are bit better than 50/50 that it will go through because it is staying there or thereabouts so the amount of sellers at 11p will be reducing as buyers keep loading up around this level. Again, as its only an odds game, there will be some (like me) foolish enough to buy before the breakout is confirmed post 11p, believing the odds are strong enough to get in now and get an extra 5-10% before this supposed dam breaks.....
Tomorrow's the day... (I may have said that before....) :0))
Dyor etc etc
Just a little more on this, a post today from Candice.
https://www.linkedin.com/posts/candice-vendettuoli-51b9b31a1_powerpoint-presentation-activity-7203332416378150912-Sb8f?utm_source=share&utm_medium=member_desktop
Just goes to show what regulatory treacle developers have to go through, with only 8% getting a CE mark with 6-12 months, 75% doing it in 13-18 months, and 17% in 19-24, largely owing to incomplete /faulty applications.
All the more reason to get it right first time. Shrewd move I think bolstering our reg side. Might not be the sexiest part of the business (if any is!) but it must be attractive to developers who might then be inclined to outsource the whole development process to us.
On the flip side though, these kinds of delays in approval flow through to a delay in orders and manufacturing requirements.
As Yates keeps saying - we want to be a trusted one stop shop.
This again relates to Regulatory changes but to be honest is one of the better I have read from ABDX and clearly shows, I think, why the company is placing so much focus on the regulatory support aspects of its business. Fundamentally, unless you are a large player with many products then outsourcing all of the regulatory stuff to a company like us seems a much better strategic option in the new environment. And lets face it, the companies we deal with are developers, normally run by scientists. - they are unlikely I think to have the resource or inclination to navigate all the regulatory hurdles and requirements and, more importantly, they will not want to slip up and delay, or potentially waste, years of development work.
https://www.abingdonhealth.com/ivdd-to-ivdr-transition-for-lateral-flow-tests/
Started: Saintsmith, 1 Jun 2024 06:58
Last post: Djmtrading91, 2 Jun 2024 13:26
Abdx have the capability of the production of test kits
Agreed Wyn
Everything I’ve looked at on this suggests that the saliva sample is done at home and then sent off for testing. I haven’t found anything yet to say that an LFT is the method of testing and, in truth, doubt it is.
https://www.icr.ac.uk/news-archive/asco-2024-prostate-cancer-spit-test-better-for-men-with-high-genetic-risk-than-standard-blood-test
https://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-epidemiology/oncogenetics/research-projects/barcode-1
I read it too this morning and wondered if we were involved. Hard to say but on balance I would say not, but the thrust is LFT's for everything so we are in the right ball park, that's for sure.
The next results update is crucial to show profitability. The market it looks to me, is waiting for the proof rather than the expectation of us PI's.
If/when it comes though....
Forget my last - I’m assuming it’s this?
https://www.bbc.co.uk/news/articles/cw44e32veg3o#:~:text=Saliva%20tests%20carried%20out%20at,a%20year%20in%20the%20UK.
The volume demand would be massive…….has the UK got a bulk producer of lateral flow tests?
Roughly for every sell 6 shares were brought yet shares still stagnant.
Started: Muck165, 30 May 2024 18:42
Last post: Muck165, 30 May 2024 18:42
Decent article from our Nina Garrett in FemTech world yesterday.
Could possibly give a clue on other things we might be working on, or perhaps be an indicator that we might hear something re Hormona soon. Or, it could just be an article!
https://www.femtechworld.co.uk/insight/18149-abi23/
Well good luck - gotta make right decisions for you.
Wasn’t it some unknown called Buffet who said something like “the stock market is a device for transferring money from the impatient to the patient”
Don’t expect he was very successful…
Sold my 5k worth... got bored waiting.
I'll be watching to jump back in
Started: Muck165, 29 May 2024 10:19
Last post: Lucksin, 29 May 2024 10:30
Great digging as ever Muck. It just feels a bit frustrating sitting on this share as its potential for expansion seems massive. It really is one to buy now at this ridiculously low price and wait patiently for as I cant see how this company isn't going to make it big in the not so fa
Looks like Salignostics are taking their saliva technology into the cancer testing space.
https://www.linkedin.com/posts/arc-innovation-center-at-sheba_sheba-medical-center-salignostics-to-develop-activity-7201465657391988736-RI4l?utm_source=share&utm_medium=member_desktop
Nothing to indicate that this will be in the form of an LFT but it could be, and Yates has reacted to the post. It will be a while in development anyway.
Last post: Lucksin, 29 May 2024 08:12
The share price is trying so hard to creep up. Needs more buying pressure. Been pretty steady though, can't be long for that breakthrough now. Really hope the next update in early July impresses potential LTIs and that those drops in interest rates proposed over this Summer, increase sentiment and momentum too.
About 7 buys for every sell good ratio,pity shares not moving northwards.
Started: Trickymatters, 22 May 2024 16:49
Last post: TerryM1, 27 May 2024 20:00
Trickymatters
You obviously know nothing about the FCA, how many courses have you done, I had to do so many and also pass (if not I was out of a job) these useless courses I have lost count. If you have had to deal with the regulations you may have some idea what you are talking about. They are a bunch of jobsworthy box tickers, this is a view taken by many in the industry, they enforce very little, hardly anyone gets prosecuted. Take a look at the USA SEC and FINRA which is far more effective especially with insider dealing. OFAC is far more effective for money laundering, which was the system used at the Bank I worked for and the system where I also had dealing. Why do think so many companies, individuals and even charities are be de-banked, not because they laundered money but because a transaction trigged some strange rule and it costs too much money to do the investigations, spend some time on research.
In my personal life I have had to move from a broker (pulling out of UK due to ridiculous regulations) and had to move 2 accounts of companies I own from an asset manger because of change of regulations which cost me a lot of money and a lot of time. I had a good relationship with the asset manager for many years (still have), they mostly handled my accounts on a discretionary basis but with some intervention from myself to maximise tax efficacy. Change of regs and they cannot handle my accounts in a way that worked well for both of us for years. They were very good and allowed me to leave without exit charges as they saw how unfair these change of rules are. This asset manager used to deal with clients who had a few hundred thousand pounds, but after speaking with them they are not now interested in any clients with less than £2 million because of the increase in FCA regulations and therefore costs. Another great win for the FCA small investors now blocked from good quality investment services because of the FCA.
'ESG is there to try to ensure that companies are not behaving exploitatively' - Utter crap - ESG is there to appease the woke tree-huggers who make all the bloody noise. It's got absolutely zero to do with exploitation or corruption - those problems were there long, long before ESG became de-rigueur and it's still there now - no change. Furthermore, it will likely still be there when ESG has run it's course and the next flavour of the month comes along! LoL
Hilarious Terry. You are admitting you are a goon then. Cynical, not wanting to comply with the regulations. Money laundering is a problem and the worst goons get caught - there are stories every other week in the FT about court cases on the subject. Insider dealing, also a big problem for us small investors. We need Aim to get cleaned up. We need lifestyle companies off the stock exchange. We need auditors to do their job. That's what will attract more investors. You are advocating for a race to the bottom where only the banks and the brokers win. That's what puts people off investing. ESG is there to try to ensure that companies are not behaving exploitatively. The fact that you see it as a tick box exercise is very telling. Gross.
In the meantime ABDX are well placed for a prentative approach to healthcare that a Labour government wants. Bring it on.
Trickymatters
"you get all these goons turn up"
So which one of my points makes me a goon, they are all facts if you bother to do the research or have been caught out by them you would know. I had a role in large investment bank and had to implement some of the rules, they did nothing but tick boxes. There is a saying in the industry, the FCA regulate for the last crisis, in other words the close the door after the horse has bolted.
The money laundering regulations do very little except get people and small companies debanked due to the cost of compliance, far cheaper just to get rid of a small customer than do £1000s of investigation just to meet the regs even if you know there is nothing wrong but was flagged up for some meaningless reason. I ended up with 2 of my business accounts I had for years locked for months because of KYC, a real struggle to get the freed up.
In order keep my job I was forced to do many courses and pass all the tests which were completely irrelevant to my job to meet the FCA rules, they were regarded as a joke but cost companies a lot of money.
As I said companies that are not registered in the UK and do no business in the UK must produce ESG reports to list on the LSE, so usually do not bother and lists elsewhere. The ESG reporting regulations makes not one jot of difference but adds costs and not in force on any other exchanges, one of the many reasons companies are leaving the LSE or listing elsewhere.
Perhaps you should try dealing with the FCA rules on a professional basis then you too would be a goon in your eyes.
You don't think companies should show commitment to ESG? Who are you? Crispin Odey or someone like him who should be preparing for trial by now?
Interesting whenever the FCA get mentioned on an investors board you get all these goons turn up. The vast majority of retail investors will benefit from a more powerful FCA with an extended remit to clean up Aim. More people will give investing a go when it starts to feel less like a casino. Who will lose? The lifestyle companies and the dodgy brokers. Who will gain? Retail investors and decent companies including micro companies with real substance to them like this one.
Started: Muck165, 27 May 2024 06:23
Last post: Muck165, 27 May 2024 06:23
We’ve been saying on here for a while that part of the ABDX allure is the move towards decentralised health care and, with it, the need for home testing.
Seems the FDA likes the idea too, having now launched its Home as a Health Care Hub initiative.
The future of healthcare will, imo, look very different to what it is today, and ABDX are very well positioned to take advantage.
https://www.fda.gov/medical-devices/medical-devices-news-and-events/fda-launches-health-care-home-initiative-help-advance-health-equity?utm_source=FDALinkedin
Last post: Muck165, 24 May 2024 17:42
I’ve been reading more and more about Bird Flu concerns, particularly in the US.
Here is the latest example
https://www.bbc.co.uk/news/articles/clee5685w19o
Interesting then that our Liam Currivan put this post out today
https://www.linkedin.com/posts/liam-currivan-8bab88135_could-the-avian-flu-be-our-next-pandemic-activity-7199325420444413952-nPrF?utm_source=share&utm_medium=member_desktop
So, he says“ Perhaps we need a #lateralflow rapid antigen test to be developed for infection monitoring...”.
I wonder, is that a hint that we might already be working on one for a customer?
Started: teraferma, 21 May 2024 12:41
Last post: Muck165, 21 May 2024 19:00
Well, the only new comment I can see is; “ Our next objective is to commence deliveries to our inaugural customers this summer.”
“Deliveries” might suggest they already have orders, and that would mean manufacturing by us.
There must be a reason?
Interesting to see they’ve only just put something out on this given they got UKCA in March!
We are thrilled to announce a significant milestone: Loop Diagnostics has received the UK-CA Mark certification as an In Vitro Diagnostic (IVD) for our SeptiLoop device, enabling its clinical use in the UK!
https://www.linkedin.com/posts/loopdx_ukcamark-septiloop-ivd-activity-7198646838399242240-rz0E?utm_source=share&utm_medium=member_desktop
Last post: Muck165, 20 May 2024 17:38
Nice post from 52 North, and so is the comment from the National Clinical Lead for Innovation at NHS England.
https://www.linkedin.com/posts/52north_spotlight-on-the-nhs-clinical-entrepreneur-activity-7198268800885026816-XGf3?utm_source=share&utm_medium=member_desktop
Ooh, like the sound of that Muck. Reckon there could be a pretty high chance as it's a market- disruptive product.
For anybody unaware, Boots is owned by Walgreen Boots Alliance Inc, which ranks #18 of the largest US companies by revenue and has over 9,000 stores across all 50 US states as well as internationally. So if Salistick were to get FDA approval then I think there’s a fair chance it will find its way into those stores, particularly given Boots are now selling it under its own brand.
May be wishful thinking I know!